Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.

[1]  C. Mantzoros,et al.  Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. , 2020, Diabetes & metabolism.

[2]  A. Vyas,et al.  PDG2 EFFICACY OF PIOGLITAZONE IN IMPROVING LIVER HISTOLOGY SCORES OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC-REVIEW AND META-ANALYSIS , 2019, Value in Health.

[3]  B. Zinman,et al.  Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial , 2018, Diabetologia.

[4]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[5]  E. Tsochatzis,et al.  The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD) , 2018, Hormones.

[6]  N. Fushimi,et al.  Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study , 2018, Diabetes, obesity & metabolism.

[7]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis , 2018, Diabetes Care.

[8]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[9]  K. Inukai,et al.  Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial , 2017, Diabetes Care.

[10]  E. Paschetta,et al.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis , 2017, JAMA internal medicine.

[11]  R. Ma,et al.  Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease , 2017, European journal of gastroenterology & hepatology.

[12]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[13]  A. Roverato,et al.  Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis , 2016, Journal of gastroenterology and hepatology.

[14]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[15]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[16]  Roy Taylor,et al.  Effect of Vildagliptin on Hepatic Steatosis , 2015, The Journal of clinical endocrinology and metabolism.

[17]  A. Arj,et al.  The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial , 2013, Hepatitis monthly.

[18]  R. Loomba,et al.  Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.

[19]  J. Hoofnagle,et al.  The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis , 2007, Hepatology.

[20]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[21]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.